RX daytona/imola /daytona plus/monaco
We develop a range of applications for the RX daytona/ imola/ daytona plus/ monaco analysers so that laboratories worldwide can enjoy the benefits of freedom of choice from an independent manufacturer, Randox Laboratories. We have a range of assays available for the RX daytona/ imola/ daytona plus/ monaco, and we are always developing more applications. If you don’t see the application you are looking for, please contact us to request an application.
All kits are produced to international standard and have ISO 13485 accreditation.
Existing customers can access IFU’s through Powerline.
Rx daytona/imola /daytona plus/monaco - Reagents
Complement Component 3 CRP Full Range (0.3-160mg/l) IgE CRP
Complement Component 4 CRP High Sensitivity IgG IgA IgM Rheumatoid Factor BASIC METABOLIC PROFILE
Calcium Creatinine Enzymatic Potassium CO2 Total
Creatinine (Jaffe) Sodium Chloride Glucose
Alkaline Phosphatase Calcium Phosphorus Total Protein
Cholesterol CRP Full Range (0.3-160mg/l) Direct LDL Cholesterol Myoglobin
CK-MB CRP High Sensitivity Heart-Type Fatty Acid Binding Protein (H-FABP) sLDL
CK-NAC Digoxin Homocysteine Triglycerides
CRP Direct HDL Cholesterol Lipoprotein (a) COMPREHENSIVE METABOLIC PROFILE
Albumin Direct Bilirubin Creatinine (Jaffe) Sodium
Alkaline Phosphatase Calcium Glucose Total Bilirubin
ALT Chloride Lactate Total Protein
AST (GOT) CO2 Total Potassium Urea
Cholesterol Direct HDL Cholesterol Glycerol Ranbut (Hydroxybutyrate)
Creatinine Enzymatic Direct LDL Cholesterol HbA1c/Hb Total Protein
Creatinine (Jaffe) Fructosamine Microalbumin Triglycerides
Cystatin C Glucose NEFA (Non-Esterified Fatty Acids) Urinary Protein
Calcium CO2 Total Magnesium Sodium (Direct / Nondirect)
Chloride (Direct / Nondirect) Lithium Potassium (Direct / Nondirect) HAEMOLYTIC ANAEMA
G-6-P-DH Haptoglobin LDH HEPATIC FUNCTION
Albumin Cholinesterase Haptoglobin Total Bilirubin
Aldolase Complement C3 IgA Total Protein
Alkaline Phosphatase Complement C4 IgG Transferrin
Alpha-1 Antitrypsin Direct Bilirubin IgM Transthyretin (Prealbumin)
ALT Gamma GT Iron (UIBC) Ammonia
GLDH Leucine Arylamidase (LAP) AST (GOT) Glycerol
LDH INFLAMMATION AND INFECTION
Acid Phosphatase ASO Lactate Alpha-1Acid Glycoprotein
CRP Rheumatoid Factor LIPIDS
Apolipoprotein A-I Apolipoprotein C-II Cholesterol Lipoprotein (a)
Apolipoprotein A-II Apolipoprotein C-III Direct HDL Cholesterol sLDL
Apolipoprotein B Apolipoprotein E Direct LDL Cholesterol Triglycerides
Alpha-1 Antitrypsin CRP Full Range (0.3-160mg/l) IgE CRP
CRP High Sensitivity Transthyretin (Prealbumin) NEUROLOGICAL DISORDERS (CSF)
IgA IgG IgM NUTRITIONAL STATUS
Albumin Iron Magnesium Transferrin
Copper Iron (UIBC) Potassium Transthyretin (Prealbumin)
Ferritin Lipase TIBC Zinc
Amylase LDH Pancreatic Amylase Glucose
Lipase RENAL FUNTION
Albumin Creatinine Enzymatic IgG Sodium
Ammonia Creatinine (Jaffe) LDH Phosphorus (Inorganic)
Beta-2 Microglobulin Cystatin C Magnesium Urinary Protein
Calcium Glucose Microalbumin Urea
Chloride HbA1c/Hb Potassium Uric Acid
Albumin Cholinesterase (Butyryl) HDL Superoxide Dismutase (Ransod)
Alkaline phosphatase CK-NAC Iron (UIBC) Sodium
ALT (GPT) CO2 Total Lactate Therapeutic drugs
Aldolase Copper Lactate dehydrogenase Total Protein
Ammonia Creatinine LDL Triglycerides
Amylase CRP Lipase Urea
AST (GOT) Canine CRP Magnesium Uric Acid
Bile acids Fructosamine NEFA (Non-esterified fatty acids) Urinary protein
Bilirubin Gamma-GT Phosphorus (Inorganic) Zinc
Calcium GLDH Potassium Chloride
Glucose Ranbut (Hydroxybutyrate) Cholesterol Glycerol
Glutathione Peroxidase (Ransel) TOXICOLOGY
Acetaminophen Gentamicin Phenytoin Valproic Acid
Carbamazepine Lithium Salicylate Digoxin
Phenobarbitol Theophyline Drugs of Abuse
Barbiturates Cocaine metabolite Ethanol Opiates
Benzodiazepines EDDP Methadone Cannabinoids
Ecstasy Methamphetamine SPECIFIC PROTEINS
Alpha-1 Antitrypsin ASO Cystatin C IgM
Alpha-1 Acid Glycoprotein Beta-2 Microglobulin Ferritin Lipoprotein (a)
Apolipoprotein A-I Ceruloplasmin Fructosamine Microalbumin
Apolipoprotein A-II Complement C3 Haptoglobin Myoglobin
Apolipoprotein B Complement C4 HbA1c/Hb Rheumatoid Factor
Apolipoprotein C-II CRP IgA Transthyretin (Prealbumin)
Apolipoprotein C-III CRP Full Range (0.3-160mg/l) IgE Transferrin
Apolipoprotein E CRP High Sensitivity IgG RESEARCH
Albumin Glutathione Reductase TIBC Uric Acid
Bilirubin Glutathione Peroxidase (Ransel) Total Antioxidant Status Ferritin
Superoxide Dismutase (Ransod) Transferrin Biotechnology
Glutamate Glutamine Food and Wine Testing
Acetic Acid Copper Glycerol Malic Acid
Ammonia Glucose Iron Potassium
Calcium Glucose/Fructose L-Lactic Acid Total Antioxidant Status
Reagents | Syphilis
Quantative and qualitative results available
For choice and convenience
Stable to expiry when stored at 2-8°C
- Treponema Pallidum Haemagglutination Assay (TPHA) method
- Liquid ready-to-use reagents
- Stable to expiry when stored at 2-8°C
- Qualitative or quantitative results
What is the Syphilis assay used for?
Syphilis is a chronic, contagious and often congenital venereal disease caused by Treponema pallidum. Infection results from contact with moist surfaces, originating in lesions of the epithelial tissue of the skin and mucous membranes. If untreated the disease may result in irreversible changes in the cardiovascular and nervous system. Syphilis remains a disease of high incidence, despite advances in modern antibiotic therapy.
Applications for Roche Cobas 4000 / 6000 / 8000
We develop a range of applications for the Roche Cobas Series (4000 / 6000 / 8000) analysers so that laboratories worldwide can enjoy the benefits of freedom of choice from an independent manufacturer, Randox Laboratories.
Applications available for Roche Cobas
We have 69 reagents available for the Roche Cobas Series (4000 / 6000 / 8000), and are always developing more. If you don’t see the application you are looking for, please email us to request an application. All kits are produced to international standard and have ISO 13485 accreditation.
D-3 Hydroxybutyrate (Ranbut)
Fructosamine (Glycated Protein)
Glutathione Peroxidase (Ransel)
Rheumatoid Factor (RF)
Superoxide Dismutase (Ransod)
Total Antioxidant Status(TAS)
Total Iron Binding
Applications for Beckman Coulter AU Series
We develop a range of applications for the Beckman Coulter AU Series (400 / 480 / 600 / 640 / 680 / 2700 / 5400 / 5800 / DxC700AU) analysers so that laboratories worldwide can enjoy the benefits of freedom of choice from an independent manufacturer, Randox Laboratories.
Beckman Coulter AU Series Applications
We have 89 reagents available for the Beckman Coulter AU (400 / 480 / 600 / 640 / 680 / 2700 / 5400 / 5800 / DxC700AU) analysers, and are always developing more. If you don’t see the application you are looking for, please contact us to request an application. All kits are produced to international standard and have ISO 13485 accreditation.
CRP Full Range
CRP High Sensitivity
LD Lactate – Pyruvate
LD Pyruvate – Lactate
Rheumatoid Factor (RF)
Superoxide Dismutase (Ransod)
Total Antioxidant Status (TAS)
Total Iron Binding
Randox Cardiology Reagents Panel
Randox is a leading provider of diagnostic reagents for the assessment of cardiovascular disease risk. Our extensive menu of cardiac biomarkers within the cardiology reagents panel include: routine lipid tests such as Homocysteine, hsCRP, Apo A-I, Apo A-II, Apo B and Lp(a), as well as, unique assays for cardiac risk assessment including sdLDL Cholesterol, Apo C-II, Apo C-III and Apo E. Check out our benefits below.
Randox Cardiology Reagents
- CK-MB useful in patients with chest pain; Creatine Kinase is an enzyme produced in many different types of cells, of which high levels indicate muscle trauma or damage.
- Myoglobin, a small protein which leaks out of muscle cells after injury, is also considered a biomarker for the detection of Myocardinal Infraction.
- Routine lipid tests to determine the patient’s cholesterol and triglyceride levels – HDL Cholesterol, LDL Cholesterol, Total Cholesterol and Triglycerides
- Independent risk assessment tests such as sdLDL Cholesterol and Lipoprotein(a) to determine any genetic factors which may increase their risk of CVD. Please note, this is necessary even for patients who have good cholesterol levels
- Secondary tests, such as High Sensitivity CRP, in addition to risk assessment markers and lipid evaluation – secondary tests are important in predicting future cardiac events of individuals with no previous history of CVD and those deemed healthy as a result of primary tests; approximately half of all heart attacks occur in patients classified as low risk. In addition, they can also be used to evaluate the risk of a recurrent cardiac event
- Speciality tests include
- Homocysteine – elevated levels of homocysteine have been linked to various disease states including CVD. Extremely high levels are found in patients with homocystinuria, of which many suffer from early arteriosclerosis.
Introducing The Randox Lipids Panel
Cardiovascular disease (CVD) caused by atherosclerosis (arteriosclerosis) is the leading cause of morbidity and mortality in Western countries1. Atherosclerosis involves the hardening and narrowing of vessels in the systemic system. This process originates from the build-up of fatty deposits through a process known as atherogenesis. If the build-up increases, plaque rupturing may occur which may lead to myocardial infarction2.
The mission of the National Lipid Association (NLA) “is to enhance the practice of lipid management in clinical medicine”. NLA advocate advancing the current lipid testing profile. The current lipid panel consists of testing LDL cholesterol, HDL cholesterol and triglycerides, which only detects approximately 20% of all atherosclerotic cardiovascular disease (ASCVD) patients. Advanced lipid testing is recommended to optimise patient treatment3.
75% of circulatory risk factors are preventable4
1 in 4 deaths in the US is attributed to heart disease6
6 million people in the UK suffer from narrowing of the heart arteries5
How Can Randox Help With The Current Challenges
As the current lipid panel consists of testing LDL cholesterol, HDL cholesterol and triglycerides, which only detects approximately 20% of all coronary artery disease (CAD) patients, advanced lipid testing is recommended to optimise patient treatment. The Randox lipid profile encompasses niche and superior performance assays for the detection of conventional risk factors, as well as emerging biomarkers associated with further risk.
Apolipoprotein C-III (Apo C-III)
A niche product from Randox, Apo C-III deficiency has shown to increase the rate of triglyceride clearance from plasma by up to 7 fold. Apo C-III levels have been reported higher in several conditions such as type 2 diabetes, hyperbilirubinemia and decreased thyroid function.
Apolipoprotein E (Apo E)
A niche product from Randox, Apo E has been found to have an association with neurodegenerative conditions such as Alzheimer’s Disease and Multiple Sclerosis. A deficiency in Apo E gives rise to high levels of serum cholesterol and triglycerides, leading to premature atherosclerosis
HDL3 Cholesterol (HDL3-C)
A niche product from Randox, HDL3-C, a subclass of HDL-C, has an inverse correlation with CVD risk. Several clinical studies indicate that measuring these HDL-C subclasses better reflects primary and secondary CHD risk than measurement of total HDL-C, making it a significant independent biomarker for better risk profiling when used together with other risk markers.
Lipoprotein (a) (Lp(a))
A unique product from Randox, Lp(a) has proven to have a causal role in the premature development of atherosclerosis and CVD as elevated Lp(a) levels associate robustly and specifically with increased CVD risk. The Randox Lp(a) assay is one of the only methodologies on the market that detects the non-variable part of the Lp(a) molecule and therefore suffers minimal size related bias.
Small-dense LDL Cholesterol (sdLDL-C)
A niche product from Randox, sdLDL-C, a subtype of LDL cholesterol, can more readily permeate the inner arterial wall. Research indicates that individuals with a predominance of sdLDL-C have a 3-fold increased risk of myocardial infarction.
Liquid ready-to-use assays
The Randox lipid assays are available in a liquid ready-to-use format for convenience and ease of use. (The Triglycerides kit is also available in a lyophilised format).
Wide measuring ranges
The Randox lipid assays can comfortably detect levels outside of the healthy range for the accurate detection of abnormal levels, offering peace of mind in patient samples.
Excellent correlation with standard methods
The Randox lipid assays display excellent correlations when compared against standard methods, offering trust and confidence in results.
Applications are available
Applications are available detailing instrument-specific settings for the convenient use of the Randox lipid assays on a wide range of clinical chemistry analysers.
Cardiovascular disease (CVD) refers to disease of the heart or blood vessels. Heart disease encompasses a number of diseases that affect the heart. In contrast, vascular disease encompasses a number of diseases that affect the blood vessels. Circulatory health problems are the result of vascular disease. Developing problems within the vascular system can go undetermined and in some patients the problem may only become apparent when they experience a heart attack or stroke 7.
Atherogenesis and Atherosclerosis
Atherogenesis is a circulatory disease whereby atheromas are formed (plaque build-up) within the artery. Plaque is a combination of cholesterol, fat, calcium, lipids and other substances within the blood stream. As time progresses, the plaque hardens, narrowing the arteries. This is known as atherosclerosis. Consequently, blood flow through the narrowed artery is reduced, limiting the supply of blood to vital organs and bodily tissues. As atherogenesis can affect any artery within the body, different diseases may develop based on the artery that is affected. Such diseases include: coronary heart/artery disease, carotid artery disease, peripheral artery disease and chronic kidney disease8.
As atherogenesis and atherosclerosis causes plaque to build up and harden within the arteries precipitating thrombi, blood flow to the heart, brain, or the lower extremities is obstructed (depending on the artery affected). This can further develop into coronary heart/artery disease (heart), ischemic stroke (brain) or peripheral vascular disease (lower extremities). However, the most common and most discussed of these manifestations is coronary heart/artery disease9. These manifestations occur when the plaque ruptures. The risk of the plaque rupturing is determined by the type of plaque (composition) rather than the size of the plaque (volume) as only plaques that are rich in soft extracellular lipids are rupture-prone (vulnerable). Whilst most plaque ruptures are small causing an acute coronary event, the actual vulnerability of the plaque may change over time. Luckily, the vulnerable plaque components are most likely to regress with treatment10.
The processes of atherogenesis, atherosclerosis and plaque rupturing, if left undetected can a myocardial infarction (MI) or “heart attack” if the plaque build-up has occurred in the coronary artery11. MI occurs when the blood supply to heart is completely blocked by the formation of a clot or a blockage due to a loose piece of atheroma (plaque rupturing). If the blood supply to the heart is blocked the cells in the heart begin to die due to the lack of oxygen, causing chest pain (angina). The extent of the blockage and the amount of heart muscle affected will determine whether this malfunction will affect the hearts ability to pump blood12. The signs of atherogenesis, atherosclerosis and plaque rupturing can be subtle, and most heart attack victims may only feel symptoms in the days leading up to the attack. For 80% of people, the first sign of a heart attack is angina. Other symptoms to be aware of are shortness of breath, anxiety, sweating, light-headedness and temporary changes in vision 11.
Regular exercise has a major effect on your circulation and cardiovascular health. Moderate levels of exercise can increase blood flow and reduce the risk of poor circulatory health conditions such as atherosclerosis. Exercise promotes good circulation as it strengthens the heart muscles, lowing the resting heart rate and preventing the build-up of plaque in the arteries. It is important for those with current circulation problems to be vigilant while exercising to ensure they are not over exerting themselves13.
Know your healthy fats
Diet changes are important for improving circulatory health. Eating a variety of foods such as lean meats, vegetables, fruits, legumes and whole grains will aid in lowering lipid levels and keep them low. It is recommended that more unsaturated fats are consumed in comparison to saturated fats, as saturated fats raise sdLDL-C levels which can lead to an increased risk of atherosclerosis. On the other hand, unsaturated fats such as monounsaturated or polyunsaturated fats may increase HDL levels and are known as being ‘heart-healthy’. It is recommended to find healthier alternatives for certain foods such as butter and oil14.
Smoking can cause circulatory problems in several ways. Most notably it can cause the carotid arteries (arteries which supply oxygen to the brain) to become filled with plaque. Also, smoking can cause PAD by reducing adequate blood supply to the limbs which can lead to leg pain and possibly amputation. Quitting smoking has been proven to have positive effects on circulation: just 20 minutes after a cigarette, blood pressure decreases and oxygen levels return to normal. Within 24 hours, the chance of a heart attack will have already decreased and after 48 hours, nerve endings deeded by the habit are expected to regenerate, with sense of taste and smell improving also. A year after quitting, the risk of coronary heart disease (CHD) will be halved. After 15 years, a quitter’s risk of CHD is now similar to that of a person who has never smoked14.
Cardiology Testing Panel
Featured Reagent Home
Reagents Resource Hub
 Burnett, John R. Lipids, Lipoproteins, Atherosclerosis and Cardiovascular Disease. National Center for Biotechnology Information (NCBI). [Online] Clin Biochem Rev., 25 February 2004. [Cited: 3 December 2018.] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1853363/.
 Zimmermaann, Kim Ann. Circulatory Systenm: Facts, Function & Diseases. Live Science. [Online] 16 March 2018. [Cited: 3 December 2018.] https://www.livescience.com/22486-circulatory-system.html.
 National Lipid Association. National Lipid Association Releases Updated Recommendations on the Use of PCSK9 Inhibitors at the 15th Annual Scientific Session. [Online] no date. [Cited: 3 December 2018.] https://www.lipid.org/nla/national-lipid-association-releases-updated-recommendations-use-pcsk9-inhibitors-15th-annual.
 World Heart Federation. Driving Sustainable Action for Circulatory Health: Whitepaper for Circulatory Health. [Online] Global Coarlition for Circulatory Health, no date. [Cited: 30 November 2018.] https://www.world-heart-federation.org/wp-content/uploads/2018/11/White-Paper-for-Circulatory-Health.pdf.
 British Heart Foundation. Research into atherosclerosis: 4 scientists talk about their work. [Online] no date. [Cited: 30 November 2018.] https://www.bhf.org.uk/informationsupport/heart-matters-magazine/research/atherosclerosis..
 Centers for Disease Control and Prevention. Heart Disease Facts. [Online] 28 November 2017. [Cited: 4 December 2018.] https://www.cdc.gov/heartdisease/facts.htm.
 Cardiovascular Disease. NHS. [Online] NHS UK, September 15, 2018. [Cited: November 30, 2018.] https://www.nhs.uk/conditions/cardiovascular-disease/
 National Heart, Lunch, and Blood Institute. Atherosclerosis. [Online] no date. [Cited: 28 November 2018.] https://www.nhlbi.nih.gov/health-topics/atherosclerosis.
 Fog Bentzon, Jacob, et al. Mechanisms of Plaque Formation and Rupture. Circulation Research. [Online] 6 June 2014. [Cited: 29 November 2018.] https://www.ahajournals.org/doi/abs/10.1161/circresaha.114.302721.
 Falk, E. Why do plaques rupture? National Center for Biotechnology Information. [Online] Circulation, December 1992. [Cited: 29 November 2018.] https://www.ncbi.nlm.nih.gov/pubmed/1424049.
 MedBroadcast. Heart Attack (Myocardial Infarction, MI). [Online] no date. [Cited: 30 November 2018.] https://medbroadcast.com/condition/getcondition/heart-attack.
 Harvard Health Publications. Heart Attack (Myocardial Infarction. [Online] 10 September 2018. [Cited: 30 November 2018.] https://www.drugs.com/health-guide/heart-attack-myocardial-infarction.html.
 Bergeson Becco, Laine. How Exercise Affects Circulation (and Vice Versa). Experience Life. [Online] June 2017. [Cited: 4 December 2018.] https://experiencelife.com/article/how-exercise-affects-circulation-and-vice-versa/.
 Mayo Clinic. Top 5 lifestykle changes to improve your cholesterol. [Online] 11 August 2018. [Cited: 4 December 2018.] https://www.mayoclinic.org/diseases-conditions/high-blood-cholesterol/in-depth/reduce-cholesterol/art-20045935.
Bile Acids Reagents
Features & Benefits of the Randox Bile Acids reagents
The Randox Bile Acids method is linear up to a concentration of 150 µmol/l
Exceptional correlation with standard methods
The Randox methodology was compared against other commercially available methods and the Randox Bile Acids assay showed a correlation coefficient of 0.99
Liquid ready-to-use reagent
A two shot ready-to-use liquid format which is more convenient as the reagent does not need to be reconstituted which aids in reducing the risk of errors occurring
Measuring range 1.47 – 150 µmol/l
Protocols are available for a range of analysers
Stable to expiry when stored at +2 to +8°C
What are Bile Acids used for?
Measuring total bile acid (TBA) levels may prove useful for the detection of liver diseases such as viral hepatitis, mild liver injury through drug use and for further evaluation of patients with chronic hepatitis who were previously treated successfully. TBA levels may rise up to 100 times the normal concentration in patients with liver disease due to impairment of hepatic synthesis and extraction of bile acids. Measurement of TBA in serum can be used in the diagnosis and prognosis of liver diseases and may detect some forms of liver disease earlier than standard liver markers due to the correlation of TBA with liver function, rather than liver damage.
Bile Acid Deficiency
TBA deficiency is caused by a genetic error in one of the 17 enzymes that produce bile acids. Deficiency can lead to liver failure and even death in infants, therefore early detection is vital. People with TBA deficiency may exhibit symptoms, including:
• Vitamin deficiencies, specifically of fat-soluble vitamins such as A, D, E, and K
• Stunted or abnormal growth
• Loss of liver function
• Liver failure
Intrahepatic Cholestasis of Pregnancy
Intrahepatic cholestasis of pregnancy (ICP) or obstetric cholestasis is a pregnancy-specific liver disorder. It can be indicated by pruritus, jaundice, elevated TBA levels and/or serum transaminases and usually affects women during the second and third trimester of pregnancy. ICP is a condition that restricts the flow of bile through the gallbladder resulting in a build-up of TBA in the liver. Due to the build-up, Bile Acids leak into the bloodstream where they are detected at concerning levels. It is an extremely serious complication of pregnancy that can lead to the increased risk of premature birth or even stillbirth as such it is vital that women with the condition are monitored carefully.
According to several reports TBA levels in ICP can reach as high as 100 times the upper limit of a normal pregnancy. It has been reported that a doubling in maternal serum TBA levels, results in a 200% increased risk of stillbirth. Additionally, bile acids can affect the foetal cardiovascular system as it has been found that there are often cardiac rhythm disturbances in the foetus due to the elevated TBA in circulation.
There are several risk factors associated with ICP such as family history, use of oral contraceptives, assisted reproduction techniques and multiple gestation. Genetic influence accounts for approximately 15% of ICP cases. Dietary selenium is a contributing environmental factor as serum selenium levels often decrease throughout pregnancy. Further to this, incidences of ICP rise in the winter months and are most likely due to the fact selenium levels are naturally less during these months. In healthy pregnancies, there is very little increase in TBA levels although a slight increase is likely to be seen in the third trimester.
Measurement of TBA in serum is thought to be the most suitable method of diagnosing and monitoring ICP.
Bile acids are water-soluble and amphipathic end products of cholesterol metabolism formed in the liver. Bile is stored in the gall bladder and released into the intestine when food is consumed. The fundamental role of bile acids is to aid in the digestion and absorption of fats and fat-soluble vitamins in the small intestine. In doing so, bile acids have five physiological functions within the body as shown below:
Determining the cause and extent of liver damage is important in guiding treatment decisions and preventing disease progression. Standard liver function tests include; ALT, AST, ALP, GGT and Bilirubin. The measurement of TBA is most beneficial in conjunction with these standard liver tests and offers unrivalled sensitivity allowing identification of early stage liver dysfunction.
There are several commercial methods available for the detection and measurement of TBA in serum. Traditional TBA tests based on the enzymatic method use nitrotetrazolium blue (NBT) to form a formazan dye. The reaction is measured at 546nm and the intensity of the colour is proportional to the concentration of bile acids.
Newer methods such as the enzyme cycling method or fifth generation methods offer many advantages including greater sensitivity, liquid reagents, small sample volumes and reduced instrument contamination from formazan dye. Additionally, the fifth generation assay does not suffer from interference from lipaemic or haemolytic samples. Both lipaemia and haemolysis are common in new-borns and pregnant women.
Enzyme cycling methods offer superior analytical performance, two reactions are combined. In the first reaction, bile acids are oxidised by 3-α hydroxysteroid dehydrogenase with the subsequent reduction of Thio-NAD to Thio-NADH. In the second reaction, the oxidised bile acids are reduced by the same enzyme with the subsequent oxidation of NADH to NAD. The rate of formation of Thio-NADH is determined by measuring the specific absorbance change at 405nm. Enzyme cycling means multiple Thio-NAD molecules are generated from each bile acid molecule giving rise to a much larger absorbance change and signal amplification, increasing the sensitivity of the assay.
The assay principle is demonstrated in the diagram below:
The Randox fifth generation assay utilises the advanced enzyme cycling method which displays outstanding sensitivity and precision compared to traditional enzymatic based tests. The assay shows excellent linearity of up to 188 µmol/l with the normal upper range of TBA in a fasting serum sample being at 10 µmol/l. The liquid ready-to-use reagent is available along with complementary controls and calibrators for a complete testing package.
Applications for Abbott Alinity Analysers
Randox have developed a range of applications for use on Abbott Alinity Analysers. Readily available applications from Randox allows laboratories worldwide to easily enjoy the benefits of freedom of choice, from an independent manufacturer whilst enjoying the benefits of the Randox panel of reagents.
Available applications for Abbott Alinity
We currently have 17 reagents available for the Abbott Alinity, and we are always developing more, therefore if you don’t see the specific application you are looking for, please email us to request an application. All kits are produced to international standard and have ISO 13485 accreditation.
Reagent | Apolipoprotein A-II
Key benefits of the Randox Apolipoprotein A-II reagent
Exceptional measuring range
The Randox albumin assay has a measuring range 6.75-61.1 mg/dl for the comfortable detection of results.
Stable to expiry when stored at 2-8°C
Liquid ready-to-use reagents
The Randox Apolipoprotein A-II reagent comes in a liquid format which is more convenient, and can also help reduce the risk of errors occurring
Applications available detailing instrument-specific settings for a variety of clinical chemistry analysers.
What is Apolipoprotein A-II assay used for?
Apolipoproteins are proteins on the surface of the lipoprotein complex that bind to specific enzymes or transport proteins on the cell membranes. This directs the lipoprotein to the proper site of metabolism. APO A-II is mainly created in the liver and modulates lipoprotein lipase and hepatic triglyceride lipase. It also acts as a co-factor for Lecithin Cholesterol Acyltransferase which is involved in lipoprotein processing.
Apolipoprotein A-II is a major constituent of High Density Lipoprotein (HDL) particles and plays an important role in the reverse cholesterol transport and lipid metabolism. The APO A-II test can be used as an aid in assessing the risk of CVD.
Reagent | Apolipoprotein A-I
Key benefits of the Randox Apolipoprotein A-I reagent
Exceptional measuring range
The Randox albumin assay has a measuring range 5.27 – 251mg/dl for the comfortable detection of results.
The Randox Apolipoprotein A-I reagent is stable to expiry when stored at 2-8°C
Applications available detailing instrument-specific settings for a variety of clinical chemistry analysers.
Liquid ready-to-use reagents
Liquid format which is more convenient, and can also help reduce the risk of errors occurring
What is Apolipoprotein A-I assay used for?
The Apolipoproteins are the main form of protein found in High Density Lipoproteins (HDL). The main role of APO A-I is in the activation of Lecithin Cholesterol Acyl Transferase (LCAT) and removal of free cholesterol from extra hepatic tissues. APO A-I may therefore be described as non atherogenic, showing an inverse relationship to cardiovascular risk.
APO A-I may be measured in patients with a personal or family history of high concentrations of lipids and/or premature CHD. It may be requested to find out the cause of high lipid levels and/or a suspected disorder that is causing a deficiency in APO A-I. APO A-I can be used with APO B-100 to check your ratio of “good” to “bad” cholesterol
- June 2022
- May 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- July 2014
- June 2014